<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28362" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Mass</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ballard</surname>
            <given-names>Brian D.</given-names>
          </name>
          <aff>McLaren Macomb Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Guzman</surname>
            <given-names>Nilmarie</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brian Ballard declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nilmarie Guzman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28362.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Renal mass is an abnormal growth in the kidney. The majority of renal masses are benign; however, a significant number of them require further intervention. This activity describes the background, evaluation, and intervention of renal mass and highlights an interprofessional team's role in improving care in patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of renal mass, specifically renal cell carcinoma.</p></list-item><list-item><p>Summarize the evaluation of renal masses.</p></list-item><list-item><p>Describe the management of patients with renal mass.</p></list-item><list-item><p>Outline some interprofessional team strategies that can improve patient outcomes in renal mass cases.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28362&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28362">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28362.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Renal masses are abnormal growths in the kidney. Most renal masses are benign; however, a significant number of them require further intervention. The retroperitoneum's anatomy, signs, symptoms, or physical examination are insufficient for detecting renal masses. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound are used to diagnose such masses. &#x000a0;Renal masses are classified into either solid or cystic. This review will focus on the solid tumor with minimal discussion on the cystic type. One of the main concerns for a solid renal mass is carcinoma. There were about 74,000 new cases in 2019; of these, it was expected that 15,000 patients would expire from cancer.</p>
        <p>The 5-year survival rate increases with early diagnosis. The survival rate for stage 1 and 2 renal cell carcinoma (RCC) is above 90% versus below 15% for certain types of stage 3 or metastatic disease.<xref ref-type="bibr" rid="article-28362.r1">[1]</xref>&#x000a0;Therefore, it is essential to diagnose and evaluate new renal masses to improve patients' quality of life and prognosis. Arguably, the most critical indication of malignancy is the size of a tumor. Renal mass is commonly divided into 2 categories: less than 4cm and more than 4cm. Because of the advancement of imaging tests such as CT, MRI, and ultrasound, more masses are detected incidentally during other workups. Results from a cross-sectional study performed in 2011 showed that renal masses are found incidentally in 14% of patients who underwent CT colonography.<xref ref-type="bibr" rid="article-28362.r2">[2]</xref>&#x000a0;Since renal mass is a diverse subject with many nuances in treatment and management, this review will explore renal mass, emphasizing small renal masses because of clinical practice relevance. We will examine the etiologies, diagnosis, and management of renal mass.</p>
      </sec>
      <sec id="article-28362.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The causes of renal mass are multifactorial. Specifically, studies have found that smoking increases RCC's risk in a dose-dependent fashion with renal cell carcinoma. Other classical precipitation agents such as benzene, herbicides, and vinyl are commonly known to increase carcinoma risk. Furthermore, medications have also been implicated. Results from a prospective study by Cho et al showed that non-steroidal anti-inflammatory drugs correlate with the increased risk of cancer.<xref ref-type="bibr" rid="article-28362.r3">[3]</xref>&#x000a0;However, this is the first kind of such study, and further evaluation and validation are needed.</p>
        <p>Genetics plays a role in the formation of renal masses as well. The most common example is polycystic kidney disease. In this condition, there are autosomal dominant and autosomal recessive forms. The recessive form is more aggressive and often fatal. Both of these have a high potential for aggressive, malignant kidney masses. Other examples of disorders associated with the development of renal masses include Von Hippel-Lindau and Birth-Hogg Dube syndromes. Interestingly, medical pathologies such as hepatitis C and kidney stones are also associated with RCC.<xref ref-type="bibr" rid="article-28362.r4">[4]</xref><xref ref-type="bibr" rid="article-28362.r5">[5]</xref></p>
      </sec>
      <sec id="article-28362.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Kidney and renal pelvic cancers are the 12th most common cancer in the United States (US), with more men affected than women. Mid-age White and Black individuals are equally affected, with Asians being the least affected. US Census found that there were around 7400 cases in 2019. There are approximately 15,000 deaths yearly, with RCC accounting for approximately 80% of those deaths. Overall, renal masses have increased in the past decades because of improved sensitivity and usage frequency of advanced imaging modalities such as MRIs and CTs. Therefore, it is not surprising to find such renal mass in healthy individuals. On the other hand, new malignant kidney mass cases have been holding steady from 2008 to 2016, with the 5-year survival rate steadily improving due to advancements in detection and intervention.</p>
      </sec>
      <sec id="article-28362.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Renal masses are frequently found incidentally without signs or symptoms. The triad of hematuria, flank pain, and flank mass is seen infrequently in modern medicine because they, more likely than not, have already been detected by imaging before symptomatology. The classic triad is observed in approximately 15% of cases, and most of those are in advanced stages. However, if these findings are present, then it warrants further evaluation. New hypertension, unintentional weight loss, and night sweats are nonspecific but essential in elucidating the differential diagnosis. Laboratory findings for anemia, polycythemia, or hypercalcemia are useful in this case. Physical examination should evaluate for varicoceles in the setting of tumor invasion.</p>
        <p>History taking should be thorough and explore information such as smoking history, eating habits, exercise status, comorbidities, and exposures to known cancer-causing agents. Literature suggests that obesity, hypertension, and smoking are present in up to 50% of cases.<xref ref-type="bibr" rid="article-28362.r6">[6]</xref>&#x000a0;Furthermore, high body mass index, triglyceride, and blood glucose seem to increase RCC risks.<xref ref-type="bibr" rid="article-28362.r7">[7]</xref>&#x000a0;Occupation exposures to dye-containing hydrocarbons have long been thought to cause RCC, but recent literature is still inconclusive, requiring further assessment. Family history and comorbidities are significant if positive. Research has linked conditions such as end-stage renal disease to RCC because of the tendency to induce the kidney's cystic formation, leading to aberrant cell formation. Also, patients with a family history of genetic conditions such as polycystic kidney disease are at a higher risk, requiring close monitoring.</p>
      </sec>
      <sec id="article-28362.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of renal mass is diverse, depending on the patient's presentation, demographic, and symptomatology. Patients with symptoms and signs such as hematuria, palpable flank mass, or flank pain should be further evaluated. Patients should undergo laboratory tests and advanced imaging such as CT, MRI, and ultrasound. The decision to use CT or MRI depends on the tumor and the patient's clinical characteristics. It is better to use CT when fast imaging acquisition is preferred or there is a contraindication to MRI, such as with patients with metallic implants. In contrast, MRI is preferred for smaller renal lesions' characterization with the benefits of no radiation exposure.</p>
        <p>It is essential to evaluate asymptomatic patients with incidental findings of renal mass. Most renal masses are benign, but there is a significant concern for carcinoma. Some signs are notable on advanced imaging to differentiate benign from malignancy. For instance, on a CT scan, fat is less dense than water and soft tissues. Therefore, Hounsfield units of less than -10 to - 20 have more fat content and likely indicate an angiolipoma, a benign tumor.<xref ref-type="bibr" rid="article-28362.r8">[8]</xref>&#x000a0;In contrast, a strong enhancement characteristic indicates that the tumor is lipid-poor with a much higher malignancy potential.</p>
        <p>If there is a suspicion of&#x000a0;renal cell carcinoma, metastasis needs to be evaluated. The most common sites for metastatic RCC are the lung (75%), followed by soft tissues, bone, liver, and brain. It is helpful to evaluate such patients with advanced imaging such as CT chest, CT brain, and bone scan. Laboratory workups include urinalysis, complete blood count, liver function test, calcium, and comprehensive metabolic panel; all are helpful in the examination. A para-neoplastic syndrome is frequently found in RCC; therefore, hyperkalemia and elevated ESR are useful markers in this setting.&#x000a0;</p>
        <p>Also, tumor size is an essential consideration in the evaluation. In general, less than 3-4 cm tumor size has lower malignant potential than larger tumors. Up to 40% of 2 cm renal masses are benign, and only a small percentage, 10%, are high-grade RCC.<xref ref-type="bibr" rid="article-28362.r9">[9]</xref><xref ref-type="bibr" rid="article-28362.r10">[10]</xref>&#x000a0;In contrast, up to 30% of 4 cm or larger renal masses are high-grade cancer.<xref ref-type="bibr" rid="article-28362.r11">[11]</xref>&#x000a0;There is a lower threshold for further evaluation with larger renal masses due to higher malignancy potential.</p>
      </sec>
      <sec id="article-28362.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Renal mass management varies depending on multiple factors, including patient size, shape, and renal tumor pathology. Different interventions include close monitoring, biopsy, surgical resection, and thermal ablation. The decision to choose one over another depends on balancing the risks and benefits. As with many other interventions, it is essential to take the age, comorbidities, risk factors, and ESRD status of a patient into consideration. For example, it is beneficial to offer patients a short life expectancy of either surveillance or ablation, depending on tumor characteristics. They are more likely to succumb to their comorbidities or surgery than from the complications of the tumor.</p>
        <p>A renal biopsy is indicated when the renal mass characteristic is unrevealing. Significant non-diagnostic results (15%) after a renal biopsy&#x000a0;require patients to undergo additional biopsies.<xref ref-type="bibr" rid="article-28362.r12">[12]</xref> There are also risks of hematoma, renal failure, and other complications. Due to its limitation, a biopsy is only indicated in certain situations. Biopsies are commonly performed when a patient is a surgical candidate, and the biopsy results help guide management. Biopsies are also of value to provide tumor pathology. Biopsies are not indicated if the result would not impact management. One typical example of when a biopsy would not be justified is when the mass is less than 1 cm. Please see Renal Biopsy by Michael Young and Stephen Leslie, published via StatPearls, for further discussion.&#x000a0;</p>
        <p>Thermal ablation is indicated in patients who are not surgical candidates. It is most useful for a tumor with a size of less than 3 cm. Ablations are less invasive than surgery; however, this increases the risk of recurrence of cancer, the need for close and active surveillance, and the potential for further treatment. Percutaneous Biopsy is recommended for post-procedural surveillance. Surgery is the most definitive intervention for malignant renal masses. The two most common approaches are partial and radical nephrectomy. Partial nephrectomy is preferred as it preserves kidney function compared to radical nephrectomy, especially in patients with chronic kidney disease stage 3 or worse.<xref ref-type="bibr" rid="article-28362.r13">[13]</xref>&#x000a0;However, there is an increase in the risk of bleeding in partial nephrectomy. Total nephrectomy should be considered when a tumor has unfavorable pathology or is larger than 5cm.<xref ref-type="bibr" rid="article-28362.r14">[14]</xref></p>
        <p>Active surveillance is indicated in many situations, especially in small masses with benign characteristics. When a tumor is less than 1cm with a gradual growth rate, further imaging and biopsy are not beneficial due to minimal malignant transformation risks. These patients should be offered active surveillance instead. Surveillance should also be offered to patients who are not surgical candidates. An elderly patient with a short life expectancy with a less than 4 cm tumor size is a suitable candidate for active surveillance. Although there is no unified guideline for the frequency of active surveillance, consensus indicates that renal ultrasound, CT, or MRI can be used for monitoring renal mass every 3 to 6 months for the first year. It can be spaced out depending on the renal pathology and progression.<xref ref-type="bibr" rid="article-28362.r15">[15]</xref></p>
      </sec>
      <sec id="article-28362.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Whenever there is a renal mass, it is always important to rule out infection and abscess, as antibiotics are required for such treatment. When an infection is ruled out, further investigation is needed for malignant etiologies such as renal cell carcinoma, metastasis, or lymphoma. While investigating malignancies, it is crucial to identify benign tumors such as oncocytoma, angiomyolipoma, or adenoma. These usually require active surveillance, with no interventions needed.</p>
      </sec>
      <sec id="article-28362.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis for renal mass depends on the tumor identified. RCC accounts for about 15,000 deaths or 80% of kidney and renal pelvic cancers. As with most other cancers, the survival rate improves with early diagnosis and treatment. According to the American Cancer Society, the localized disease in stages 1 and 2 has an above 90% survival rate, while distant metastasis, such as in stage 4, has a 13% 5-year survival rate. In stage 3, the survival rate for patients who underwent nephrectomy is up to 70%. However, invasion into the renal vein indicates a poorer prognosis.<xref ref-type="bibr" rid="article-28362.r16">[16]</xref></p>
        <p>For other types of tumors, classical variant angiomyolipomas have a prolonged growth rate. In one case report, 90% of tumors with a size of less than 1.5 cm have no growth over the 5-year follow-up.<xref ref-type="bibr" rid="article-28362.r17">[17]</xref>&#x000a0;The epithelioid variants, however, have a small but significant potential for malignant transformation. A small case series indicates that out of 40 participants, about 9 (26%) have malignant transformation.<xref ref-type="bibr" rid="article-28362.r18">[18]</xref></p>
        <p>Oncocytoma is mostly benign and well organized compared to RCC. They are encapsulated and not invasive. However, RCC can be seen in up to 30% of patients who have oncocytoma. As a result, they should be closely monitored for renal malignancy. A metanephric adenoma is mostly benign; however, it can present similarly to RCC in symptomatology. Patients can present with the classical triad of flank pain, hematuria, and a palpable mass. The critical difference is that they present more frequently in females than males, unlike their RCC counterparts. Histology is the primary way to diagnose this type of mass. Up to 90% of the adenoma have a<italic toggle="yes"> BRAF</italic> V600 mutation.<xref ref-type="bibr" rid="article-28362.r19">[19]</xref>&#x000a0;Due to the tumor pathology, there is no surgical indication since it is benign.</p>
      </sec>
      <sec id="article-28362.s10" sec-type="Complications">
        <title>Complications</title>
        <p>It is vital to balance the risks and benefits of intervention versus surveillance. When surgery is indicated, it is essential to evaluate the risk of infection, bleeding, and renal failure. Therefore, it is essential to assess patients before undergoing invasive procedures. When a patient is not a candidate for surgery, ablation is an option. Although there are fewer complications than surgery, the risk for recurrent, requiring multiple treatment sessions, is higher in the ablation group. Providers must inform patients about the risks and benefits before undergoing interventions.</p>
      </sec>
      <sec id="article-28362.s11" sec-type="Consultations">
        <title>Consultations</title>
        <p>Specialists such as oncologists and urologists should be consulted for the evaluation and management of certain renal masses.</p>
      </sec>
      <sec id="article-28362.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>It is essential to educate patients on the risk factors for renal cell carcinoma, such as smoking, alcohol use, obesity, genetic, environmental exposure, and dialysis. Patients should be counseled to quit smoking and alcohol and increase their dietary intake of vegetables and fruits. These qualities have been shown to correlate with a lower rate of renal cancer. Depending on the clinical and renal pathology, patients should be offered genetic counseling to the patient and their families, such as Von-Hippel Lindal, hereditary leiomyomatosis and renal cell cancer, Birt-Hogg-Dub&#x000e9; syndrome, and hereditary papillary renal carcinoma.</p>
        <p>Workers who have been exposed to toxic agents such as polycyclic aromatic hydrocarbon groups should be further evaluated. Still, studies have been inconclusive about the actual link of such exposure to RCC.<xref ref-type="bibr" rid="article-28362.r20">[20]</xref>&#x000a0;Literature has linked medications to renal cell carcinoma. Results from a 2011 prospective study showed that the more prolonged use of non-aspirin, non-steroid anti-inflammatory drugs correlates with increased RCC risk.<xref ref-type="bibr" rid="article-28362.r3">[3]</xref>&#x000a0;This is the first study of its kind, and further evaluation is needed to solidify this finding; therefore, it is essential to discuss the risks and benefits of their medications with patients.</p>
      </sec>
      <sec id="article-28362.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional team involvement is essential in preventing and treating renal mass. With the guidance of dietitians and physical therapists, patients can appreciate diet and weight loss for their overall health and reduce malignant renal mass risk. Primary care providers and nurses need to reinforce the importance of follow-up, medication compliance, and cessation of alcohol and cigarettes. Furthermore, urologists and oncologists, along with primary care providers and pharmacists, can optimize treatment guidance and interventions while reducing complications. By collaboration and communication, an interprofessional team will offer improved delivery of care for patients with renal masses.</p>
      </sec>
      <sec id="article-28362.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28362&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28362">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/renal-mass/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28362">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28362/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28362">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28362.s15">
        <title>References</title>
        <ref id="article-28362.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Motzer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bander</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Nanus</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Renal-cell carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>1996</year>
            <month>Sep</month>
            <day>19</day>
            <volume>335</volume>
            <issue>12</issue>
            <fpage>865</fpage>
            <page-range>865-75</page-range>
            <pub-id pub-id-type="pmid">8778606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Connor</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Pickhardt</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management.</article-title>
            <source>AJR Am J Roentgenol</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>197</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-45</page-range>
            <pub-id pub-id-type="pmid">21701022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Curhan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hankinson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Stampfer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Prospective evaluation of analgesic use and risk of renal cell cancer.</article-title>
            <source>Arch Intern Med</source>
            <year>2011</year>
            <month>Sep</month>
            <day>12</day>
            <volume>171</volume>
            <issue>16</issue>
            <fpage>1487</fpage>
            <page-range>1487-93</page-range>
            <pub-id pub-id-type="pmid">21911634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lamerato</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Chronic hepatitis C infection as a risk factor for renal cell carcinoma.</article-title>
            <source>Dig Dis Sci</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>60</volume>
            <issue>6</issue>
            <fpage>1820</fpage>
            <page-range>1820-4</page-range>
            <pub-id pub-id-type="pmid">25592719</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheungpasitporn</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Thongprayoon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>O'Corragain</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Edmonds</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Ungprasert</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kittanamongkolchai</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Erickson</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>The risk of kidney cancer in patients with kidney stones: a systematic review and meta-analysis.</article-title>
            <source>QJM</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>108</volume>
            <issue>3</issue>
            <fpage>205</fpage>
            <page-range>205-12</page-range>
            <pub-id pub-id-type="pmid">25208892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and risk factors for kidney cancer.</article-title>
            <source>Nat Rev Urol</source>
            <year>2010</year>
            <month>May</month>
            <volume>7</volume>
            <issue>5</issue>
            <fpage>245</fpage>
            <page-range>245-57</page-range>
            <pub-id pub-id-type="pmid">20448658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e4;ggstr&#x000f6;m</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rapp</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stocks</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Manjer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bj&#x000f8;rge</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ulmer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Engeland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Almqvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Concin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Selmer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ljungberg</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tretli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nagel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hallmans</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jonsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stattin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Metabolic factors associated with risk of renal cell carcinoma.</article-title>
            <source>PLoS One</source>
            <year>2013</year>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>e57475</fpage>
            <pub-id pub-id-type="pmid">23468995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davenport</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Neville</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cohan</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Leder</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging.</article-title>
            <source>Radiology</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>260</volume>
            <issue>1</issue>
            <fpage>158</fpage>
            <page-range>158-65</page-range>
            <pub-id pub-id-type="pmid">21555349</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frank</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Blute</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cheville</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lohse</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Zincke</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Solid renal tumors: an analysis of pathological features related to tumor size.</article-title>
            <source>J Urol</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>170</volume>
            <issue>6 Pt 1</issue>
            <fpage>2217</fpage>
            <page-range>2217-20</page-range>
            <pub-id pub-id-type="pmid">14634382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Vukina</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Woods</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Raynor</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Wallen</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Pruthi</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate.</article-title>
            <source>J Urol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>193</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-5</page-range>
            <pub-id pub-id-type="pmid">25072182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thompson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Kurta</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Kaag</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tickoo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nogueira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reuter</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Tumor size is associated with malignant potential in renal cell carcinoma cases.</article-title>
            <source>J Urol</source>
            <year>2009</year>
            <month>May</month>
            <volume>181</volume>
            <issue>5</issue>
            <fpage>2033</fpage>
            <page-range>2033-6</page-range>
            <pub-id pub-id-type="pmid">19286217</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutherland</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Choromanska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al-Katib</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coffey</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Outcomes of ultrasound guided renal mass biopsies.</article-title>
            <source>J Ultrasound</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-104</page-range>
            <pub-id pub-id-type="pmid">29696566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Uzzo</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Allaf</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bass</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Cadeddu</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Derweesh</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Giambarresi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gervais</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Leibovich</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Pierorazio</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Renal Mass and Localized Renal Cancer: AUA Guideline.</article-title>
            <source>J Urol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>198</volume>
            <issue>3</issue>
            <fpage>520</fpage>
            <page-range>520-529</page-range>
            <pub-id pub-id-type="pmid">28479239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Poppel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Da Pozzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Albrecht</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Matveev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bono</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Borkowski</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colombel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klotz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Marreaud</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Collette</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sylvester</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.</article-title>
            <source>Eur Urol</source>
            <year>2011</year>
            <month>Apr</month>
            <volume>59</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-52</page-range>
            <pub-id pub-id-type="pmid">21186077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordetsky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eich</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Garapati</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Del Carmen Rodriguez Pena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rais-Bahrami</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Active Surveillance of Small Renal Masses.</article-title>
            <source>Urology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>123</volume>
            <fpage>157</fpage>
            <page-range>157-166</page-range>
            <pub-id pub-id-type="pmid">30267727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Herrell</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cookson</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma.</article-title>
            <source>Urology</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>78</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <page-range>99-104</page-range>
            <pub-id pub-id-type="pmid">21550647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yip</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Management of renal angiomyolipoma: a report of 53 cases.</article-title>
            <source>BJU Int</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>84</volume>
            <issue>9</issue>
            <fpage>1116</fpage>
            <pub-id pub-id-type="pmid">10651524</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brimo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Latour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Epstein</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2010</year>
            <month>May</month>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>715</fpage>
            <page-range>715-22</page-range>
            <pub-id pub-id-type="pmid">20410812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Cheville</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Palescandolo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fay</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Kantoff</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Atkins</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>McKenney</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lampron</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hirsch</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Signoretti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>BRAF mutations in metanephric adenoma of the kidney.</article-title>
            <source>Eur Urol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>62</volume>
            <issue>5</issue>
            <fpage>917</fpage>
            <page-range>917-22</page-range>
            <pub-id pub-id-type="pmid">22727996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28362.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Capitanio</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Bensalah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bex</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Boorjian</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wood</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Renal Cell Carcinoma.</article-title>
            <source>Eur Urol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>74</fpage>
            <page-range>74-84</page-range>
            <pub-id pub-id-type="pmid">30243799</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
